Navigation Links
Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
Date:1/28/2013

potential for JVS-100, we believe having someone with Paul's experience focused on strategic opportunities will allow us to best recognize the long-term value of this platform."

"I'm thrilled to join the Juventas team," remarked Dr. Resnick.  "Juventas is pursuing a unique therapeutic strategy in the exciting field of regenerative medicine.  Through activation of a patient's own stem-cell repair processes, JVS-100 delivers regenerative benefits without the cost and complexities typically associated with cell-based therapeutics.  I look forward to applying my industry perspective and leveraging my contacts to help Juventas transition toward commercialization."

About Juventas Therapeutics

Juventas Therapeutics, headquartered in Cleveland, OH, is a privately held clinical-stage biotechnology company developing a pipeline of regenerative therapies to treat life–threatening diseases. Founded in 2007 with an exclusive license from Cleveland Clinic, Juventas has transitioned its therapeutic platform from concept to initiation of mid-stage clinical trials for treatment of heart failure and critical limb ischemia.  Investors include Triathlon Medical Ventures, New Science Ventures, Takeda Ventures, Venture Investors, Early Stage Partners, Fletcher Spaght Ventures, Reservoir Venture Partners, Glengary, The Global Cardiovascular Innovation Center, Tri-State Growth Fund, North Coast Angel Fund, X Gen Ltd., JumpStart Inc., and Blue Chip Venture Co. The company has received non-dilutive grant support through the Ohio Third Frontier-funded Cleveland Clinic Ohio BioValidation Fund, Global Cardiovascular Innovation Center and Center for Stem Cell & Regenerative Medicine.


'/>"/>
SOURCE Juventas Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Juventas Therapeutics Raises $22.2 Million Series B Financing
2. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
3. Shield Therapeutics Selects OpenClinica Enterprise
4. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
5. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
6. NKT Therapeutics Presents Data on Potential Antibody Treatment for Sickle Cell Disease
7. Cell Therapeutics Reports on Cooperative Group Sponsored Trial of Brostallicin in Patients with Metastatic Triple-Negative Breast Cancer
8. Smith & Nephew Announces Agreement To Acquire Assets Of Healthpoint Biotherapeutics
9. Intarcia Therapeutics Secures Landmark $210 Million Financing To Fund Its Global Phase 3 Program For ITCA 650 In Type 2 Diabetes
10. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
11. Cell Therapeutics, Inc. (CTI) to Present at Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 23, 2013 Venaxis, Inc. ... company focused on obtaining FDA clearance and commercializing its ... announced the pricing of an underwritten public offering of ... to purchase 3,500,000 shares of its common stock at ... combined public offering price of $1.25 per share and ...
(Date:5/23/2013)... May 23, 2013 Can economic incentives ... work motivate members of the public to increase their ... Johns Hopkins Carey Business School Assistant Professor ... Pointing to a large body of recent research that ... May 24, 2013, issue of Science that the World ...
(Date:5/23/2013)... Patheon Inc ., a leading provider of contract ... will host a complimentary webinar on “Cleaning Validation: Science, ... 4, 2013 at 11 a.m. Eastern Standard Time. ... regulations for cleaning validation. Many companies have incorporated ... evaluation of risk. Some companies have chosen to ...
(Date:5/23/2013)... -- Rahal Letterman Lanigan Racing (RLL) and StemCyte, Inc., a ... and therapeutics, announced today that StemCyte has become an ... car driven by James Jakes . ... 2013 season.   StemCyte, Inc. and Rahal Letterman ... umbilical cord blood banking and its educational initiative ,Stars ...
Breaking Biology Technology:Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 2StemCyte, Inc. Joins Rahal Letterman Lanigan Racing As Associate Sponsor Of No. 16 IndyCar Program For James Jakes Beginning With The 97th Indianapolis 500 3
... the following Webcast:, What: Neogen Corporation 3rd Quarter ... http://www.videonewswire.com/event.asp?id=46587 , How: Live over the ... above., Contact: ... participate during the live webcast, the call will,be archived on the Web ...
... March 18 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ONC, ... been,granted U.S. Patent 7,344,711 entitled "Use of Adenoviruses ... claims describe methods of treating,cancer using adenoviruses that ... have an activated Ras pathway., "This patent ...
... In video interviews Said,Darwazah, CEO, and Bassam ... plus what they are expecting from the company,in ... available,now on http://www.cantos.com ., It,s free ... register at, http://www.cantos.com . Cantos.com, the online financial ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery ... grasses , Within the genome of each species, ... little change in position and sequence over millions of ... of these evolutionarily stable sequences, so-called conserved noncoding sequences ... genes or the condensation of chromosomes, but the function ...
(Date:5/23/2013)... 13,000 ships per year, carrying more than 284 million tons ... $1.8 billion dollars in toll fees for the Panama Canal ... million gallons of water are used from Gatun Lake, which ... people living in the isthmus. , However, the advent ... percent of the ships at sea, has demanded change. The ...
Breaking Biology News(10 mins):Please do try this at home 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3Reforestation study shows trade-offs between water, carbon and timber 2Reforestation study shows trade-offs between water, carbon and timber 3
... 3 A simple blood test could predict which patients ... are soon to get far worse, an indicator that could ... University of Pittsburgh School of Medicine. Their findings, published online ... body,s immune cells attack healthy lung tissue, suggesting that IPF ...
... report on a new way of preventing potentially harmful plasticizers ... migrating from one of the most widely used groups of ... polyvinyl chloride (PVC) plastics that are safer than those now ... say. Their study is in ACS, Macromolecules , a ...
... Pennsylvania studying oocytes in mice, the immature egg cells ... in microRNA, or miRNA, activity that may be the ... blastomeres of the embryo. MicroRNAs are a member of ... of the biological world. MicroRNAs imperfectly pair with ...
Cached Biology News:Test could predict which idiopathic pulmonary fibrosis patients will become severely ill 2Penn biologists determine microRNA activity is suppressed in mouse ovum 2
... discovery projects require screening through a ... clinically relevant data from normal biologic ... is now available to help better ... data flood inherent to biomarker discovery. ...
... Using multicolor analysis in a modern flow ... cells that are differentially labeled with fluorescent ... dyes typically used for cell labeling are ... by a flow cytometers filters. Thus, the ...
This free-standing laminar flow hood provides a vertical flow of HEPA-filtered air to create a clean processing area. It includes a fluorescent light and motorized sliding shield. Options include wor...
... Orbit LS Low Speed Shaker ... low speed shaker is a high quality, general ... ,Styled after the other models in the ... design with easy-access control panel. Electronic controls are ...
Biology Products: